Tag Archives: Proteasome

Kyprolis versus Velcade in Phase 3 Study in Previously-Treated Patients

In a Phase 3 study of 929 patients with previously treated multiple myeloma, two proteasome inhibitors, Velcade (bortexomib – Johnson & Johnson and Takeda) ) and Kyprolis (carfilzomib – Amgen), in combination with dexamethasone, were compared. Patients treated with Kyprolis had a median progression-free survival of 18.7 months, versus 9.4 months for those treated with Velcade.

Kyprolis versus velcade

Continue reading

Kyprolis FOCUS Phase 3 Study for Multiple Myeloma

Last week, Amgen (Onyx) announced negative news from its FOCUS clinical trial of multiple myeloma drug Kyprolis. Let’s put this into perspective. Continue reading